dabrafenib,trametinib,pembrolizumab
merck,novartis
['melanoma', 'neotrio', 'keynote 716', 'pembro']
great to be at #asco2022 &amp; reviewing data for #melanoma pts: short-course braf+mek does not appear to enhance pd1 activity on neoadjuvant platform ( neotrio trial); pembrolizumab decreases the risk of dmfs c/f placebo (keynote 716); pathcr rate 55% desmoplastic mel. 
Co-Medical Director and Medical Oncologist Melanoma Institute Australia.